RANI
Rani Therapeutics Holdings Inc Class A (RANI)
Healthcare • NASDAQ • $0.64+0.25%
- Symbol
- RANI
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $0.64
- Daily Change
- +0.25%
- Market Cap
- $90.02M
- Trailing P/E
- N/A
- Forward P/E
- -3.37
- 52W High
- $3.87
- 52W Low
- $0.61
- Analyst Target
- $7.20
- Dividend Yield
- 0.00%
- Beta
- 0.71
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat rheumatoid arthritis; RT-116 which is in discovery stage for the treatment of obesity; RT-117 for rare diseases; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The company has a co…
Company websiteResearch RANI on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.